PDF
Progress Toward the Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Worldwide, 2016–2021
Organization: United States Centers for Disease Control (CDC)Published: 2022
Abstract
What is already known about this topic?
Mother-to-child transmission of hepatitis B virus (HBV), a leading cause of liver cancer, is targeted for global elimination.
What is added by this report?
During 2016–2020, global coverage with the third dose of hepatitis B vaccine remained between 82% and 85%, whereas timely coverage with hepatitis B birth dose increased from 37% to 43%. Coverage in 2020 was ≥90% for both the hepatitis B birth dose and the 3-dose series of hepatitis B vaccine in 41% of countries. In 11 countries, prevalence of HBV surface antigen among children was ≤0.1%.
What are the implications for public health practice?
Accelerating hepatitis B birth dose introduction, increasing coverage with the third dose of hepatitis B vaccine, and monitoring programmatic and impact indicators are essential for elimination of mother-to-child transmission of HBV.
Product Type: Report
Category:
Vaccine Preventable Diseases,Vaccine Preventable Disease Surveillance,Global Surveillance,Communicable Diseases,Hepatitis B Vaccine Preventable DiseasesVaccine Preventable Disease Surveillance
Global Surveillance
Communicable Diseases
Hepatitis B
Population: Infants
Children (All)
Adolescents
Pregnant and Breastfeeding People
Region: International
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.